Pre-Tax margin is calculated as Pre-Tax Income divided by its Revenue. Genfit's Pre-Tax Income for the
six
months ended in Dec. 2025 was €-76.40 Mil. Genfit's Revenue for the
six
months ended in Dec. 2025 was €31.95 Mil. Therefore, Genfit's pretax margin for the quarter that ended in Dec. 2025 was -239.14%.
The historical rank and industry rank for Genfit's Pretax Margin % or its related term are showing as below:
FRA:XUPB'
s Pretax Margin % Range Over the Past 10 Years
Min: -115760.87 Med: -172.65 Max: 86.77
Current: -132.19
FRA:XUPB's Pretax Margin % is ranked worse than 54.14% of 942
companies
in the Biotechnology industry
Industry Median: -90.5
vs FRA:XUPB: -132.19
Genfit (FRA:XUPB) Pretax Margin % Explanation
The pretax margin, as know as pretax profit margin, is widely used to measure the operating efficiency of a company before deducting taxes.
The pretax margin is sometimes preferred over the net margin as tax expenditures can make profitability comparisons between companies misleading.
It is a useful tool to compare companies operating in the same sector and less effective when comparing companies from other sectors as each industry generally has different operating expenses and sales patterns.
The long term trend of the pretax margin is a good indicator of the competitiveness and health of the business.
Genfit Pretax Margin % Related Terms
Genfit Pretax Margin % Historical Data
* Premium members only.
The historical data trend for Genfit's Pretax Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
FRA:XUPB vs VRTX, REGN, ALNY: Pretax Margin % Comparison
For the Biotechnology subindustry, Genfit's Pretax Margin %, along with its competitors' market caps and Pretax Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Genfit Pretax Margin % vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Genfit's Pretax Margin % distribution charts can be found below:
* The bar in red indicates where Genfit's Pretax Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Genfit (FRA:XUPB) has a Pretax Margin % of -239.14% as of Dec. 2025. Pre-Tax margin is the ratio of total pre-tax income to net sales. View historical data on Genfit and its competitors. According to the industry distribution chart, Genfit ranks #510 out of 942 companies in the Biotechnology industry, placing it in the top 54.1%.
Is Genfit's Pretax Margin % too high?
Genfit's current Pretax Margin % is -239.14%. Based on the distribution chart, Genfit ranks #510 out of 942 companies in the Biotechnology industry, which is below the industry midpoint. Overall, Genfit has a GF Score™ of 68/100, reflecting its overall financial health beyond just this single metric.
How does Genfit's Pretax Margin % compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Genfit ranks #510 out of 942 companies for Pretax Margin %. This places Genfit in the lower half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Pretax Margin % for a Biotechnology company?
A good Pretax Margin % depends on the Biotechnology industry context. However, Pretax Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Pretax Margin % mean?
A high Pretax Margin % can signal that a stock is expensive relative to its fundamentals. Pre-Tax margin is the ratio of total pre-tax income to net sales. View historical data on Genfit and its competitors. Genfit's current Pretax Margin % is -239.14%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Genfit stock overvalued right now?
Genfit (FRA:XUPB) has a current Pretax Margin % of -239.14%. The stock's GF Value™ is €5.19, compared to a current price of €6.15 — trading 18.5% above its estimated fair value. The current Pretax Margin % is -239.14%. Genfit's overall GF Score™ is 68/100 with 10 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Pretax Margin % calculated?
Pretax Margin % is calculated from a company's financial statements. For Genfit (FRA:XUPB), the current Pretax Margin % is -239.14% as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Genfit (FRA:XUPB) Overvalued in 2026?
Based on GuruFocus' analysis, Genfit stock appears to be overvalued.
The current stock price of €6.15 is trading 18.5% above its estimated GF Value™ of €5.19.
Key valuation signals for FRA:XUPB:
Pretax Margin %: -239.14%
GF Value™: €5.19 vs. price of €6.15 (18.5% above fair value)
No single metric tells the full story. See the FRA:XUPB stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Genfit SA is a biotechnology company focused on metabolic and inflammatory diseases, with a particular focus on the liver and gastroenterology. The company's research and development activity relies on its expertise in modulating gene expression through nuclear receptors. Genfit utilizes acquisitions, strategic alliances, and licensing agreements to fund the further development of its products. It has one segment, the research and development of medicines and diagnostic solutions, the marketing of which depends on the success of the clinical development phase.
68GF Score
Get the complete analysis for FRA:XUPB
Pretax Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FRA:XUPB has been successfully added to your 
